Enables protein kinase activity. Involved in protein phosphorylation. Predicted to be located in cytosol; fibrillar center; and nucleoplasm. Orthologous to human MAP3K14 (mitogen-activated protein kinase kinase kinase 14); PARTICIPATES IN nuclear factor kappa B signaling pathway; apoptotic cell death pathway; mitogen activated protein kinase signaling pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 3-phenylprop-2-enal; bisphenol A.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP3K14 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP3K14 mRNA
arsenite inhibits the reaction [MAP3K14 protein results in increased activity of CHUK protein], arsenite inhibits the reaction [MAP3K14 protein results in increased activity of IKBKB protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP3K14 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP3K14 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP3K14 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP3K14 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MAP3K14 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MAP3K14 mRNA
MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein], MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]
MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein], MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]
MAP3K14 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein], MAP3K14 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA
Protective effect of Ginkgolids (A+B) is associated with inhibition of NIK/IKK/IkappaB/NF-kappaB signaling pathway in a rat model of permanent focal cerebral ischemia.